Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour

Toxicology

Volumn 183, Issue 1-3, 2003, Pages 151-173

  Tricker, Anthony R ^a  

^a Philip Morris Products SA   (Switzerland)

Author keywords

Genetic polymorphism; Metabolism; Nicotine; Smoking behaviour

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; DIMETHYLANILINE MONOOXYGENASE; GLUCURONOSYLTRANSFERASE; LIVER ENZYME; NICOTINE; NICOTINE N' OXIDE;

AEROBIC METABOLISM; ARTICLE; CATALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GLUCURONIDATION; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; OXIDATION; PRIORITY JOURNAL; SMOKING;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; COTININE; FEMALE; HALF-LIFE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; NICOTINE; POLYMORPHISM, GENETIC; SMOKING;

NICOTIANA TABACUM;

EID: 0037291512     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00513-9     Document Type: Article

References (159)

1. Adlkofer F., Scherer G., Biber A., Heller W.-D., Lee P.N., Schievelbein H. Consistency of nicotine intake in smokers of cigarettes with varying nicotine yields. Wald N., Froggart P. Nicotine, Smoking and the Low Tar Programme. 1989;116-130 Oxford University Press, Oxford.
2. Akerman B.R., Forrest S., Chow L., Youil R., Knight M., Treacy E.P. Two novel mutations of the FMO3 gene in a proband with trimethylaminuria. Hum. Mutat. 13:1999;376-379.
3. Andersson G., Kazemi Vala E., Curvall M. The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. J. Oral Pathol. Med. 26:1997;117-123.
4. Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Takeishi T., Kobayashi S., Mizorogi Y., Loriot M.-A., Stückler I., Beaune P., Kinoshita M., Kamataki T. Structural characterisation of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics. 10:2000;687-693.
5. Ariyoshi N., Sawamura Y., Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun. 281:2001;810-814.
6. Ayesh R., Al-Waiz M., Crothers M.J., Cholerton S., Mitchell S.C., Idle J.R., Smith R.L. Deficient nicotine N-oxidation in two sisters with trimethylaminuria. Br. J. Clin. Pharmacol. 25:1988;664P-665.
7. Benowitz N.L., Jacob P. III. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin. Pharmacol. Ther. 53:1993;316-323.
8. Benowitz N.L., Jacob P. III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:1994;483-493.
9. Benowitz N.L., Jacob P. III. Individual differences in nicotine kinetics and metabolism in humans. NIDA Res. Monogr. 173:1997;48-64.
10. Benowitz N.L., Jacob P. III. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin. Pharmacol. Ther. 67:2000;653-659.
11. Benowitz N.L., Jacob P. III. trans-3′-Hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. J. Clin. Pharmacol. 51:2001;53-59.
12. Benowitz N.L., Hall S.M., Herning R.L., Jacob P., Jones R.T., Osman A.L. Smokers of low-yield cigarettes do not consume less nicotine. New Engl. J. Med. 309:1989;139-142.
13. Benowitz N.L., Jacob P. III, Fong I., Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:1994;296-303.
14. Benowitz N.L., Jacob P. III, Sachs D.P.L. Deficient C-oxidation of nicotine. Clin. Pharmacol. Ther. 57:1995;590-594.
15. Benowitz N.L., Jacob P., Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics. 6:1996;239-242.
16. Benowitz N.L., Pérez-Stable E.J., Fong I., Modin G., Herrera B., Jacob P. III. Ethnic differences in N-glucuronidation of nicotine and cotinine. J. Pharmacol. Exp. Ther. 291:1999;1196-1203.
17. Benowitz N.L., Griffin C., Tyndale R. Deficient C-oxidation of nicotine continued. Clin. Pharmacol. Ther. 70:2001;567.
18. Benowitz N.L., Pérez-Stable E.J., Herrera B., Jacob P. III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J. Natl. Cancer Inst. 94:2002;105-108.
19. Berkman C.E., Park S.B., Wrighton S.A., Cashman J.R. In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem. Pharmacol. 50:1995;565-570.
20. Bertilsson L., Lou Y.-Q., Du Y.-L., Liu Y., Huang T.-Y., Liao X.-M., Wang K.-Y., Reviriego J., Iselius L., Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51:1992;388-397.
21. Booth J., Boyland E. Enzymic oxidation of (-)-nicotine by guinea pig tissue in vitro. Biochem. Pharmacol. 20:1971;407-415.
22. Boswell C., Curvall M., Elswick R.K. Jr, Leyden D. Modelling nicotine intake in smokers and snuff users using biological fluid nicotine metabolites. Biomarkers. 5:2000;341-354.
23. Boustead C., Taber H., Idle J.R., Cholerton S. CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics. 7:1997;411-414.
24. Brandänge S., Lindblom L. The enzyme 'aldehyde oxidase' is an iminium oxidase. Reaction with nicotine Δ-1′(5′) iminium ion. Biochem. Biophys. Res. Commun. 91:1979;991-996.
25. Byrd G.D., Chang K.-M., Greene J.M., deBethizy J.D. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab. Dispos. 20:1992;192-197.
26. Byrd G.D., Robinson J.H., Caldwell W.S., deBethizy J.D. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology. 122:1995a;95-103.
27. Byrd, G.D., Davis, R.A., Kazemi Vala, E., 1995b. Comparison of methods for determining nicotine and its metabolites in urine, Poster #9, Conference of the Society for Research on Nicotine and Tobacco, 24-25 March, San Diego, CA.
28. Byrd G.D., Davies R.A., Caldwell W.S., Robinson J.H., deBethizy J.D. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology. 139:1998;229-291.
29. Caldwell W.S., Greene J.M., Byrd G.D., Chang K.M., Uhrig M.S., deBethizy J.D., Crooks P.A., Bhatti B.S., Riggs R.M. Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. Chem. Res. Toxicol. 5:1992;280-285.
30. Caporaso N.E., Lerman C., Audrain J., Boyd N.R., Main D., Issaq H.J., Utermahlan B., Falk R.T., Shields P. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol. Biomarkers Prev. 10:2001;261-263.
31. Cashman J.R., Park S.B., Yang Z.-C., Wrighton S.A., Jacob P. III, Benowitz N.L. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol. 5:1992;639-646.
32. Cashman J.R., Bi Y.-A., Lin J., Youil R., Knight M., Forrest S., Treacy E. Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem. Res. Toxicol. 10:1997;837-841.
33. Cashman J.R., Zhang J., Leushner J., Braun A. Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab. Dispos. 29:2001;1629-1637.
34. Chen G.-F., Tang Y.-M., Green B., Lin D.-X., Guengerich F.P., Daly A.K., Caporaso N.E., Kadlubar F.F. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics. 9:1999;327-332.
35. Cholerton S., Arpanahi A., McCracken N., Boustead C., Taber H., Johnstone E., Leathart J., Daly A.K., Idle J.R. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet. 343:1994;62-63.
36. Cholerton S., Boustead C., Taber H., Arpanahi A., Idle J.R. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics. 6:1996;261-263.
37. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., Waxman D.J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25:1997;985-993.
38. Crawford E.L., Weaver D.A., DeMuth J.P., Jackson C.M., Khuder S.A., Frampton M.W., Utell M.J., Thilly W.G., Willey J.C. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis. 19:1998;1867-1871.
39. Curvall M., Kazemi Vala E., Enzell C.R., Wahren J. Simulation and evaluation of nicotine intake during passive smoking: cotinine measurements in body fluids of nonsmokers given intravenous infusions of nicotine. Clin. Pharmacol. Ther. 47:1990;42-49.
40. Curvall M., Kazemi Vala E., Englund G. Conjugation pathways in nicotine metabolism. Adlkofer F., Thurau K. Effects of Nicotine on Biological Systems. 1991;69-75 Birkhäuser Verlag, Basel.
41. Degawa M., Stern S.J., Martin M.V., Guengerich F.P., Fu P.P., Ilett K.F., Kaderlik R.K., Kadlubar F.F. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res. 54:1994;4915-4919.
42. Dempsey D., Jacob P. III, Benowitz N.L. Nicotine metabolism and elimination kinetics in newborns. Clin. Pharmacol. Ther. 67:2000;458-465.
43. Dempsey D., Jacob P. III, Benowitz N.L. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J. Pharmacol. Exp. Ther. 301:2002;594-598.
44. Diago S., Takahashi Y., Fujieda M., Ariyoshi N., Yamazaki H., Koizumi W., Tanabe S., Saigenji K., Nagayama S., Ikeda K., Nishioka Y., Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 12:2002;299-306.
45. Dolphin C.T., Janmohamed A., Smith R.L., Shephard E.A., Phillips I.R. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat. Genet. 17:1997;491-494.
46. Edwards R.J., Adams D.A., Watts P.S., Davies D.S., Boobis A.R. Development of a comprehensive panel of antibodies against major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem. Pharmacol. 56:1998;377-387.
47. Elkins S., Wrighton S.A. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:1999;719-754.
48. Fernandez-Salguero P., Gonzalez F.J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 5:1995;S123-S128.
49. Fernandez-Salguero P., Hoffman S.M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J., Evans W.E., Idle J.R., Gonzalez F.J. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. S7:1995;651-660.
50. Flammang A.M., Gelboin H.V., Aoyama T., Gonzales F.J., McCoy G.D. Nicotine metabolism by cDNA-expressed human cytochrome P-450s. Biochem. Arch. 8:1992;1-8.
51. Forrest S.M., Knight M., Akerman B.R., Cashman J.R., Treacy E.P. A novel deletion in the flavin-containing monoxygenase gene (FMO3) in a Greek patient with trimethylaminuria. Pharmacogenetics. 11:2001;169-174.
52. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 9:1999;295-306.
53. Ghosheh O., Vashishtha S.C., Hawes E.M. Formation of the quaternary ammonium-linked glucuronide of nicotine in human liver microsomes: identification and stereoselectivity in the kinetics. Drug Metab. Dispos. 29:2001;1525-1528.
54. Gorrod J.W., Hibberd A.R. The metabolism of nicotine-Δ-1′(5′)-iminium ion, in vivo and in vitro. Eur. J. Drug Metab. Pharmacokinet. 7:1982;293-298.
55. Gorrod J.W., Schepers G. Biotransformation of nicotine in mammalian systems. Gorrod J.W., Jacob P. III. Analytical Determination of Nicotine and Related Compounds and their Metabolites. 1999;45-67 Elsevier, Amsterdam.
56. Gough A.C., Smith C.A., Howell S.M., Wolf C.R., Bryant S.P., Spurr N.K. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridisation, and linkage analysis. Genomics. 15:1993;430-432.
57. Gourlay S.G., Kenkare S., Benowitz N.L. Effects of the menstrual cycle on nicotine pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 71:2002;P33.
58. Green M.D., Tephly T.R. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab. Dispos. 26:1998;860-867.
59. Gu D.F., Hinks L.J., Morton N.E., Day I.N.M. The use of long PCR to confirm three common alleles at the CYP2A6 locus and relationship between genotype and smoking habit. Ann. Hum. Genet. 64:2000;383-390.
60. Gullstén H., Agúndez J.A.G., Benítez J., Läärä E., Ladero J.M., Díaz-Rubio M., Fernandez-Salguero P., Gonzalez F., Rautio A., Pelkonen O., Raunio H. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. Pharmacogenetics. 7:1997;247-250.
61. Guillemette C., Ritter J.K., Auyeung D.J., Kessler F.K., Housman D.E. Structural heterogeneity at the UGT-glucuronosyltransferase 1 locus: functional consequences of three novel missence mutations in the human UGT1A7 gene. Pharmacogenetics. 10:2000;629-644.
62. Hadidi H., Zahlsen K., Idle J.R., Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 35:1997;903-907.
63. Hecht S.S., Carmella S.G., Murphy S.E. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol. Biomarkers Prev. 8:1999;907-913.
64. Hellmold H., Rylander T., Magnusson M., Reihnér E., Warner M., Gustafsson J.-A. Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J. Clin. Endocrinol. Metab. 83:1998;886-895.
65. Hoffman S.M.G., Fernandez-Salguero P., Gonzalez F.J., Mohrenweiser H.W. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J. Mol. Evol. 41:1995;894-900.
66. Idle J.R. CYP2A6 polymorphism, nicotine, and environmental nitrosamines. Lancet. 353:1999;2073.
67. Inoue K., Yamazaki H., Shimada T. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch. Toxicol. 73:2000;532-539.
68. Iscan M., Rostami H., Iscan M., Güray T., Pelkonen O., Rautio A. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol. 47:1994;315-318.
69. Jarvis M.J., Russell M.A.H., Benowitz N.L., Feyerabend C. Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am. J. Public Health. 78:1988;696-698.
70. Kalow W., Grant D.M. Pharmacogenetics. Scriver C.R., Benudet A., Sly W., Valle D. The Metabolic and Molecular Basis of Inherited Disease. seventh ed. 1995;293-326 MaGraw-Hill Book Company, New York.
71. Kivisto K.T., Griese E.U., Stuven T., Fritz P., Friedel G., Kroemer H.K., Zanger U.M. Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics. 7:1997;295-302.
72. Kitagawa K., Kunugita N., Katoh T., Yang M., Kawamoto T. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem. Biophys. Res. Commun. 262:1999;146-151.
73. Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem. 267:2001;17830-17835.
74. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., Anttila S., Fernandez-Salguero P., Gonzalez F., Raunio H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57:1999;1407-1413.
75. Kwon J.-T., Nakajima M., Chai S., Yom Y.-K., Kim H.-K., Yamazaki H., Sohn D.-R., Yamamoto T., Kuroiwa Y., Yokoi T. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 11:2001;317-323.
76. Kyerematen G.A., Morgan M.L., Chattopadhyay B., deBethizy J.D., Vesell E.S. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin. Pharmacol. Ther. 48:1990;641-651.
77. 85Y). Cancer Epidemiol. Biomarkers Prev. 9:2000;329-333.
78. Lang D.H., Yeung C.K., Peter R.M., Ibarra C., Gasser R., Itagaki K., Philpot R.M., Rettie A.E. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem. Pharmacol. 56:1998;1005-1012.
79. Lang T., Klein K., Fischer J., Nüssler A.K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., Zanger U.M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 11:2001;399-415.
80. Langmann P., Bienert A., Zilly M., Väth T., Richter E., Klinker H. Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis. Eur. J. Med. Res. 5:2000;217-221.
81. Lechevrel M., Casson A.G., Wolf C.R., Hardie L.J., Flinterman M.B., Montesano R., Wild C.P. Characterization of cytochrome P450 expression in human oesophageal mucosa. Carcinogenesis. 20:1999;243-248.
82. London S.J., Idle J.R., Daly A.K., Coetzee G.A. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet. 353:1999;890-898.
83. Loriot M.-A., Rebuissou S., Oscarson M., Cenée S., Miyamoto M., Ariyoshi N., Kamataki T., Hémon D., Beaune P., Stückler I. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics. 11:2001;39-44.
84. Macé K., Bowman E.D., Vautravers P., Shields P.G., Harris C.C., Pfeifer A.M.A. Characterization of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer. 34:1998;914-920.
85. Mackenzie P.I., Miners J.O., McKinnon R.A. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical significance. Clin. Chem. Lab. Med. 38:2000;889-892.
86. Marez D., Legrand M., Sabbagh N., Guidice J.M., Spire C., Lafitte J.J., Meyer U.A., Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterisation of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 7:1997;193-202.
87. McCracken N.W., Cholerton S., Idle J.R. Cotinine formation by cDNA-expressed human cytochromes P450. Med. Sci. Res. 20:1992;877-878.
88. Meger, M., Meger-Kossien, I., Schuler-Metz, A., Janket, D., Scherer, G., 2002. Simultaneous determination of nicotine and eight metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry, J. Chromatogr., in press.
89. Merkel U., Sigusch H., Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur. J. Clin. Pharmacol. 46:1994;175-177.
90. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282:1997;1608-1614.
91. Miles J.S., McLaren A.W., Forrester L.M., Glancey M.J., Lang M.A., Wolf C.R. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267:1990;365-371.
92. Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., Nemoto N., Sato K., Ariyoshi N., Kamataki T. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261:1999;658-660.
93. Molander L., Hansson A., Lunell E., Alainentalo L., Hoffmann M., Larsson R. Pharmacokinetics of nicotine in kidney failure. Clin. Pharmacol. Ther. 68:2000;250-260.
94. Molander L., Hansson A., Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clin. Pharmacol. Ther. 69:2001;57-65.
95. Murphy P.J. Enzymatic oxidation of nicotine to nicotine Δ-1′(5′) iminium ion. A newly discovered intermediate in the metabolism of nicotine. J. Biol. Chem. 248:1973;2796-2800.
96. Murphy S.E., Johnson L.M., Pullo D.A. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem. Res. Toxicol. 12:1999;639-645.
97. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24:1996a;1212-1217.
98. Nakajima M., Yamamoto T., Nunoya K., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996b;1010-1015.
99. Nakajima M., Yamagishi S., Yamamoto H., Yamamoto T., Kuroiwa Y., Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin. Pharmacol. Ther. 67:2000;57-69.
100. Nakajima M., Kwon J.-T., Tanaka N., Zenta T., Yamamoto Y., Yamamoto H., Yamazaki H., Yamamoto T., Kuroiwa Y., Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. 68:2001;72-78.
101. Nowak M.P., Sellers E.M., Tyndale R.F. Canadian native Indian exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin. Pharmacol. Ther. 64:1998;378-383.
102. Nowell S., Sweeney C., Hammons G., Kadlubar F.F., Lang N.P. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 11:2002;377-383.
103. Nunoya K., Yokai T., Kimura K., Inoue K., Kodoma T., Funayama M., Nagashima K., Funae Y., Green C., Kinoshita M., Kamataki T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidine-4-one hydrochloride (SM-12502). Pharmacogenetics. 8:1998;239-249.
104. Nunoya K., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. 289:1999a;437-442.
105. Nunoya K., Yokoi T., Takahashi K., Kimura K., Kinoshita M., Kamataki T. Homozygous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metaboliser phenotype. J. Biochem. 126:1999b;402-407.
106. Oates, N.S., Ayesh, R., Cartmel, B., Idle J.R., 1987. Influence of smoking on the distribution of the debrisoquine metabolic ratio, Proceedings of Xth International Congress on Pharmacology, p. 91.
107. Oscarson M., Gullstén H., Rautio A., Bernal M.L., Sinues B., Dahl M.-L., Stengård J.H., Pelkonen O., Raunio H., Ingelman-Sundberg M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 438:1998;201-205.
108. Oscarson M., McLellan R.A., Gullstén H., Agúndez J.A.G., Benítez J., Rautio A., Pelkonen O., Ingelman-Sundberg M. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. 460:1999a;321-327.
109. Oscarson M., McLellan R.A., Gullstén H., Yue Q.-Y., Lang M.A., Bernal M.L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:1999b;105-110.
110. Park S.B., Jacob P. III, Benowitz N.L., Cashman J.R. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem. Res. Toxicol. 6:1993;880-888.
111. Pasanen M., Rannala Z., Tooming A., Sotaniemi E.A., Pelkonen O., Rautio A. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology. 123:1997;177-184.
112. Paschke T., Riefler M., Schuler-Metz A., Wolz L., Scherer G., McBride C.M., Bepler G. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology. 168:2001;259-268.
113. Pelkonen O., Pasanen M., Kuha H., Gachalyi B., Kairaluoma M., Sotaniemi E.A., Park S.S., Friedman F.K., Gelboin H.V. The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies. Br. J. Clin. Pharmacol. 22:1986;125-134.
114. Pérez-Stable E.J., Herrera B., Jacob P. III, Benowitz N.L. Nicotine metabolism and intake in black and white smokers. J. Am. Med. Assoc. 280:1998;152-156.
115. Pianezza M.L., Sellers E.M., Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature. 393:1998;750.
116. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 284:2001;455-460.
117. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., Tyndale R.F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58:2000;747-755.
118. Rauma A.-L., Rautio A., Pasanen M., Pelkonen O., Törrönen R., Mykkänen H. Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet. Eur. J. Clin. Pharmacol. 50:1996;133-137.
119. Rautio A., Gullstén H., Pelkonen O., Raunio H. Polymorphism of CYP2A6: correlation between genotype and phenotype. Pharmacol. Toxicol. 80:(Suppl. 3):1997;P7-2.
120. Ren Q., Murphy S.E., Zheng Z., Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab. Dispos. 28:2000;1352-1360.
121. Rossing M.A. Genetic influences on smoking: candidate genes. Environ. Health Perspect. 106:1998;231-238.
122. Russell M.A.H., Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab. Rev. 8:1978;29-57.
123. Saarikoski S.T., Sata F., Husgafvel-Pursiainen K., Rautalahti M., Haukka J., Impivaara O., Järvisalo J., Vainio H., Hirvonen A. CYP2D6 ultrarapid metaboliser genotype as a potential modifier of smoking behaviour. Pharmacogenetics. 10:2000;5-10.
124. Sabol S.Z., Hamer D.H. An improved assay shows no association between the CYP2A6 gene and cigarette smoking behaviour. Behav. Genet. 29:1999;257-261.
125. Satarug S., Lang M.A., Yongvanit P., Sithithaworn P., Mairiang E., Mairiang P., Pelkonen P., Bartsch H., Haswell-Elkins M.R. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, Opisthorchiasis viverrini. Cancer Epidemiol. Biomarkers Prev. 5:1996;795-800.
126. Schepers G., Demetriou D., Rustemeier K., Voncken P., Diehl B. Nicotine phase 2 metabolites in human urine - structure of metabolically formed trans-3′-hydroxycotinine glucuronide. Med. Sci. Res. 20:1992;863-865.
127. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology. 145:1999;1-20.
128. Scherer G., Jarczyk L., Heller W.-D., Biber A., Neurath G.B., Adlkofer A. Pharmacokinetics of nicotine, cotinine, and 3′-hydroxycotinine in cigarette smokers. Klin. Wochenschr. 66:(Suppl. XI):1988;5-11.
129. Schulz T.G., Ruhnau P., Müller M., Bünger J., Elliehausen H.J., Hallier E. Lack of correlation between CYP2A6 genotype and smoking habits. Toxicology. 164:2001a;150-151.
130. Schulz T.G., Ruhnau P., Hallier E. Lack of correlation between CYP2A6 genotype and smoking habits. Adv. Exp. Med. Biol. 500:2001b;213-215.
131. Seaton M.J., Vesell E.S. Variables affecting nicotine metabolism. Pharmacol. Ther. 60:1993;461-500.
132. Seaton M.J., Vesell E.S., Luo H., Hawes E.M. Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. J. Chromatogr. 621:1993;49-53.
133. Sellers E.M. Pharmacogenetics and ethnoracial differences in smoking. J. Am. Med. Assoc. 280:1998;179-180.
134. Shimada T., Yamazaki H., Guengerich F.P. Ethnic-related differences in coumarin 7-hydroxylation activities catalysed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 26:1996;395-403.
135. Siegle I., Fritz P., Eckhardt K., Zanger U.M., Eichelbaum M. Cellular localisation and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics. 11:2001;237-245.
136. Sotaniemi E.A., Rautio A., Bäckstrom M., Arvela P., Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney disease and epileptic patients. Br. J. Clin. Pharmacol. 39:1995;71-76.
137. Sotaniemi E.A., Lumme P., Arvela P., Rautio A. Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Therapie. 51:1996;363-366.
138. Su T., Sheng J.J., Lipinskas T.W., Ding X. Expression of CYP2A genes in rodent and human nasal mucosa. Drug Metab. Dispos. 24:1996;884-890.
139. Tan W., Chen G.-F., Song C.-Y., Yang M., Kadlubar F.F., Lin D.-X. CYP2A6 gene deletion and susceptibility to lung cancer and esophageal cancer in a Chinese population. Proc. Am. Assoc. Cancer Res. 41:2000;591.
140. Tan W., Chen G.-F., Xing D.-Y., Song C.-Y., Kadlubar F.F., Lin D.-X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer. 95:2001;96-101.
141. Tiihonen J., Pesonen U., Kauhanen J., Koulu M., Hallikainen T., Leskinen L., Salonen J.T. CYP2A6 genotype and smoking. Mol. Psychiatry. 5:2000;347-348.
142. Turgeon J., Labbé L., Lefez C., LeBel M. Debrisoquine metabolic ratio (DMR) distribution differs among smokers and non-smokers. Clin. Pharmacol. Ther. 57:1995;150.
143. Tyndale R.F., Sellers E.M. Variable CYP2A6-mediated nicotine metabolism alters smoking behaviour and risk. Drug Metab. Dispos. 29:2001;548-552.
144. Tyndale R.F., Rao Y., Bodin L., Zeman M.V., Hoffmann E., Sellers E.M. CYP2A6 gene defects and duplications alter objective indices of smoking. Nicotine Tobacco Res. 2:2000;308.
145. Vincent-Viry M., Fournier B., Galteau M.M. The effect of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab. Dispos. 28:2000;617-619.
146. Wewers M.E., Ahijevych K.L., Dhatt R.K., Guthrie R.M., Kuun P., Mitchell L., Moeschberger M.L., Chen M.S. Jr. Cotinine levels in Southeast Asian smokers. Nicotine Tobacco Res. 2:2000;85-91.
147. Willey J.C., Coy E.L., Frampton M.W., Torres A., Apostolakos M.J., Hoehn G., Schuermann W.H., Thilly W.G., Olson D.E., Hammersley J.R., Crespi C.L., Utell M.J. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am. J. Respir. Cell Mol. Biol. 17:1997;114-124.
148. Xu C., Rao Y.S., Xu B., Hoffmann E., Jones J., Sellers E.M., Tyndale R.F. An in vivo pilot study characterising the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun. 290:2002;318-324.
149. Yamano S., Nagata K., Yamazoe Y., Kato R., Gelboin H.V., Gonzalez F.J. cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). Nucleic Acids Res. 17:1989;4888.
150. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
151. Yamazaki H., Inoue K., Hashimoto M., Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol. 73:1999;65-70.
152. Yang M., Kunugita N., Kitagawa K., Kang S.H., Coles B., Kadlubar F.F., Katoh T., Matsuno K., Kawamoto T. Individual difference in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolising enzymes. Cancer Epidemiol. Biomarkers Prev. 10:2001;589-593.
153. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolising enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm. Res. 15:1998;517-524.
154. Yun C.-H., Shimada T., Guengerich F.P. Purification and characterisation of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40:1991;679-685.
155. Zabetian C.P., Gelernter J., Cubells J.F. Functional variants at CYP2A6: New genotyping methods, population genetics, and relevance to studies of tobacco dependence. Am. J. Med. Genet. (Neuropsychiatr. Genet.). 96:2000;638-645.
156. Zanger U.M., Fischer J., Raimundo S., Stüven T., Evert B.O., Schwab M., Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11:2001;573-585.
157. Zevin S., Jacob P. III, Geppetti P., Benowitz N.L. Clinical
158. Zhang X., Ameno K., Ameno S., Iwahashi K., Kinoshita H., Kubota T., Mostofa J., Ijiri I. Lack of association between smoking and CYP2A6 gene polymorphisms in a Japanese population. Jpn. J. Alcohol Drug Depend. 36:2001;486-490.
159. Zhou X., Gu J., Zhang Q.Y., Spink D.C., Kaminsky L.S., Ding X. Biotransformation of coumarin by rodent and human cytochromes P450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J. Pharmacol. Exp. Ther. 288:1999;463-471.